- Abstract:
-
BACKGROUND: Somatostatin analogs (SA) have been used for over 25 years in the treatment of acromegaly. A major disadvantage is the need to continue therapy indefinitely. OBJECTIVE: To evaluate the feasibility of discontinuing therapy in well-controlled patients with acromegaly treated chronically with SA. DESIGN AND METHODS: Of the 205 subjects on octreotide LAR, we selected those who met the following criteria: two or more years of treatment, a stable dose and injection interval of 20 mg e...
Expand abstract - Publication status:
- Published
- Journal:
- European journal of endocrinology / European Federation of Endocrine Societies
- Volume:
- 166
- Issue:
- 1
- Pages:
- 21-26
- Publication date:
- 2012-01-05
- DOI:
- EISSN:
-
1479-683X
- ISSN:
-
0804-4643
- URN:
-
uuid:e91e54bb-68ac-4569-91a6-616f5b03f5e4
- Source identifiers:
-
221322
- Local pid:
- pubs:221322
- Language:
- English
- Keywords:
- Copyright date:
- 2012
Journal article
Discontinuation of octreotide LAR after long term, successful treatment of patients with acromegaly: is it worth trying?
Actions
Authors
Bibliographic Details
Item Description
Terms of use
Metrics
Altmetrics
Dimensions
If you are the owner of this record, you can report an update to it here: Report update to this record